2019
DOI: 10.1016/j.jclepro.2019.117719
|View full text |Cite
|
Sign up to set email alerts
|

Reverse flows within the pharmaceutical supply chain: A classificatory review from the perspective of end-of-use and end-of-life medicines

Abstract: A classificatory literature review on medicines reverse flows is performed. Excessive production/demand uncertainty jeopardize medicines reverse flows. Cordination of the forward supply chain is pivotal for medicines reverse logistics. Green chemistry is a form of circular economy in pharmaceutical supply chain. Failures in monitoring of prescriptions hinder the circularity of medicines. Circular economy of medicines requires deeper investigation as business opportunity.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
29
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 51 publications
(30 citation statements)
references
References 142 publications
0
29
0
1
Order By: Relevance
“…On the other hand, since utilizing meta-heuristic algorithms is the most suitable method in tackling such NP-hard problems, there are several previous papers in this field. Instances contain Devika et al (2014) , Vahdani et al (2017) , Sabouhi et al (2018) , Fakhrzad et al (2018) , Mani and Gunasekaran (2018) , Fakhrzad et al (2019) , Roshan et al (2019) , Ghasemi et al (2019) , Goodarzian and Hosseini-Nasab (2019) , Govindan et al (2019) , Viegas et al (2019) , Halim et al (2019) , Zandkarimkhani et al (2020) , Ghasemi and Khalili-Damghani (2020) , Liu et al, 2020a , Liu et al, 2020b , Goodarzian et al (2020a) , Ghasemi et al (2020) , Ang et al (2020) , Goodarzian et al (2020b) , Goodarzian et al (2021) , and Fathollahi-Fard et al (2020) .…”
Section: Literature Reviewmentioning
confidence: 99%
“…On the other hand, since utilizing meta-heuristic algorithms is the most suitable method in tackling such NP-hard problems, there are several previous papers in this field. Instances contain Devika et al (2014) , Vahdani et al (2017) , Sabouhi et al (2018) , Fakhrzad et al (2018) , Mani and Gunasekaran (2018) , Fakhrzad et al (2019) , Roshan et al (2019) , Ghasemi et al (2019) , Goodarzian and Hosseini-Nasab (2019) , Govindan et al (2019) , Viegas et al (2019) , Halim et al (2019) , Zandkarimkhani et al (2020) , Ghasemi and Khalili-Damghani (2020) , Liu et al, 2020a , Liu et al, 2020b , Goodarzian et al (2020a) , Ghasemi et al (2020) , Ang et al (2020) , Goodarzian et al (2020b) , Goodarzian et al (2021) , and Fathollahi-Fard et al (2020) .…”
Section: Literature Reviewmentioning
confidence: 99%
“…The reverse logistics is based on all the logistic activities required to transform used products into reusable products [79]. Being products classified according to the remaining useful life and their status, the information to be gathered on the product side are product condition [80], product lifecycle stage, product design, inventory of returned products, product perishability, product complexity and hazardous material composition [81]. Moreover, considering the uncertainties regarding the returned products, there should be the necessity to gather data regarding time, quality, quantity, and types of returned products, to then develop a plan and decide whether to recondition, reuse or sell the returned product in a secondary market [49].…”
Section: Closed-loop Supply Chain and Reverse Logisticsmentioning
confidence: 99%
“…Cost effectiveness analysis for a complete medicine reuse ecosystem based on the proposed IoPT concept is a complicated process which mainly involves (i) direct costs such as setup cost, running cost and product cost, (ii) indirect costs such as enhancing public health and reduce environmental pollution, and (iii) shared cost with pharmaceutical supply chain management such as Circular Economy (CE) [38]. Bekker et al [39] review the pharmacy's running cost and conclude that a re-dispensing of returned medicines is more effective for expensive medicines.…”
Section: Cost Effectivenessmentioning
confidence: 99%